| Abstract: |
Treatment options have improved for patients with colorectal cancer, but these improvements have invariably been more modest than had been anticipated or hoped for.Yetwhile outcomes have improvedmodestly, costs have risen substantially, as prices of the newer anticancer agents in colorectal cancer have led theway in the stratospheric rise in cancer drug prices in general. Development of future strategies thatwill be both sustainable and attainable by allwho need themwill require both an understanding of past events that have brought us to the present and a willingness to confront the limitations of our present options and to assess them for the true value that they do or do not offer. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. |
